描述(Description)
The HEK293/Human B7-H4 Stable Cell Line was engineered to express the receptor full length human B7-H4(Gene ID: 79679), used to mimic cancer target cells. Surface expression of human B7-H4 was confirmed by flow cytometry.
应用说明(Application)
• Useful for cell-based B7-H4 binding assay
生长特性(Growth Properties)
Adherent
筛选标记(Selection Marker)
Puromycin (2 μg/mL)
培养基(Culture Medium)
DMEM + 10% FBS
冻存液(Freeze Medium)
Serum-free cell cryopreservation medium
装量(Quantity)
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储(Storage)
Frozen in liquid nitrogen.
支原体检测(Mycoplasma Testing)
Negative
无菌检测(Sterility Testing)
Negative
使用说明(Instructions for Use)
See data sheet for detailed culturing and assay protocol.
Receptor Assay
Expression analysis of human B7-H4 on HEK293/Human B7-H4 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human B7-H4 Stable Cell Line or negative control cell using PE-labeled anti-human B7-H4 antibody.
Protocol
如有相关细胞池需求请联系我们
背景(Background)
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) is also known as Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, B7H4, which belongs to the immunoglobulin superfamily and BTN/MOG family. VTCN1 contains two Ig-like V-type (immunoglobulin-like) domains. The expression of VTCN1 is up-regulated by IL6 and IL10 and is inhibited by GM-CSF and IL4 on antigen-presenting cells (APCs). VTCN1 / B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. VTCN1 involved in promoting epithelial cell transformation.
Permits & Restrictions
This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.